{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:58:51Z","timestamp":1770908331040,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.clml.2019.03.008","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T10:58:57Z","timestamp":1554375537000},"page":"e324-e336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting\u00a02018"],"prefix":"10.1016","volume":"19","author":[{"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.03.008_bib1","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1182\/blood-2018-154","article-title":"Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib3","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2018-99-117871","article-title":"Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","volume":"132","author":"Bustoros","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood-2018-99-114956","article-title":"A\u00a0quadruplet regimen comprising carfilzomib, cyclophosphamide, lenalidomide, dexamethasone (KCRD) vs. an immunomodulatory agent containing triplet (CTD\/CRD) induction therapy prior to autologous stem cell transplant: results of the myeloma XI study","volume":"132","author":"Jackson","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2018-99-112093","volume":"132","author":"Gay","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.008_bib7","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.008_bib8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.008_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood-2018-151","volume":"132","author":"Voorhees","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/blood-2018-99-111924","article-title":"VTD (bortezomib\/thalidomide\/dexamethasone) as pretransplant induction therapy for multiple myeloma: definitive results of a randomized phase 3 Pethema\/GEM study","volume":"132","author":"Dachs","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1182\/blood-2018-99-112899","article-title":"Double vs. single autologous stem cell transplantation for newly diagnosed multiple myeloma: long-term follow-up (10-years) analysis of randomized phase 3 studies","volume":"132","author":"Cavo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib13","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2019.03.008_bib14","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosinol","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib15","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.008_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1182\/blood-2018-99-116716","volume":"132","author":"Tacchetti","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib17","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2018-99-117964","article-title":"Tandom autologous transplantation and combined infusion of CD19 and Bcma-specific chimeric antigen receptor T cells for high risk\u00a0MM: initial safety and efficacy report from a clinical pilot study","volume":"132","author":"Shi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood-2018-99-109920","article-title":"Ixazomib-lenalidomide-dexamethasone (IRd) consolidation following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a large multi-center phase II trial","volume":"132","author":"Vij","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood-2018-99-113586","article-title":"Safety and efficacy data for combined checkpoint inhibition with ipilimumab (Ipi) and nivolumab (Nivo) as consolidation following autologous stem cell transplantation (ASCT) for high-risk hematological malignancies \u2014 CPIT-001 trial","volume":"132","author":"Skarbnik","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2018-99-112079","volume":"132","author":"Dimopoulos","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2018-99-111117","article-title":"Progression-free survival below 12 months following stem cell transplant is a hallmark of high-risk myeloma which is associated with inferior overall survival \u2014 data from the Ukmrc Myeloma XI trial","volume":"132","author":"Bygrave","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood-2018-99-111250","article-title":"Comparison of minimal residual disease detection in autografts of patients with multiple myeloma between 8-color multiparameter flow cytometry (EuroFlow) and next-generation sequencing","volume":"132","author":"Takamatsu","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib23","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1093\/annonc\/mdx340","article-title":"Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation","volume":"28","author":"Takamatsu","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.03.008_bib24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2018-99-111321","article-title":"Standardization of 18F-FDG PET\/CT according to deauville criteria for MRD evaluation in newly diagnosed transplant eligible multiple myeloma patients: joined analysis of two prospective randomized phase III trials","volume":"132","author":"Zamagni","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib25","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-120737","article-title":"Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA)","volume":"132","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2018-99-111244","article-title":"Preliminary results from a phase I study of isatuximab (ISA) in combination with bortezomib, lenalidomide, dexamethasone (VRd), and in patients with newly diagnosed multiple myeloma (NDMM) non-eligible for transplant","volume":"132","author":"Ocio","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2018-156","article-title":"One-year update of a phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) in patients (Pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): Alcyone","volume":"132","author":"Dimopoulos","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib28","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1182\/blood-2018-99-114668","article-title":"Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) in unfit and frail newly diagnosed multiple myeloma (NDMM) patients; first interim safety analysis of the phase II HOVON 143 study","volume":"132","author":"Stege","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib29","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood-2018-99-111650","volume":"132","author":"Zweegman","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood-2018-99-111796","article-title":"Efficacy and feasibility of dose\/schedule-adjusted Rd-R vs. continuous Rd in elderly and intermediate-fit newly diagnosed multiple myeloma (NDMM) patients: RV-MM-PI-0752 phase III randomized study","volume":"132","author":"Larocca","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib31","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1182\/blood-2018-99-112289","article-title":"Carfilzomib-lenalidomide-dexamethasone versus bortezomib-lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma: results from the prospective, longitudinal, observational commpass study","volume":"132","author":"Landgren","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib32","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood-2018-99-111065","article-title":"Phase 2 trial of ixazomib, lenalidomide, dexamethasone and daratumumab in patients with newly diagnosed multiple myeloma","volume":"132","author":"Kumar","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib33","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood-2018-152","article-title":"Lyra: a phase 2 study of daratumumab (Dara) plus cyclophosphamide, bortezomib, and dexamethasone (Cybord) in newly diagnosed and relapsed patients (Pts) with multiple myeloma (MM)","volume":"132","author":"Yimer","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib34","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/blood-2018-99-116624","article-title":"Carfilzomib versus bortezomib in combination with cyclophosphamide and dexamethasone for treatment of first relapse or primary refractory multiple myeloma (MM): outcomes based on genetic risk and long term follow up of the phase 2 Muk Five study","volume":"132","author":"Yong","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib35","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood-2018-99-116426","article-title":"Maintenance with carfilzomib following carfilzomib, cyclophosphamide and dexamethasone at first relapse or primary refractory multiple myeloma (MM) on the phase 2 Muk Five study: effect on minimal residual disease","volume":"132","author":"Yong","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone vs. bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.03.008_bib37","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood-2018-99-114029","article-title":"Carfilzomib, pomalidomide and dexamethasone (KPd) in patients with multiple myeloma refractory to bortezomib and lenalidomide. the EMN011 trial","volume":"132","author":"Sonneveld","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib38","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1182\/blood-2018-99-112669","article-title":"Efficacy of daratumumab in combination with standard of care regimens in lenalidomide-exposed or -refractory patients with relapsed\/refractory multiple myeloma (RRMM): analysis of the Castor, Pollux, and MMY1001 studies","volume":"132","author":"Usmani","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib39","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood-2018-99-113177","volume":"132","author":"Avet-Loiseau","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib40","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1182\/blood-2018-99-114863","article-title":"Efficacy and safety of once-weekly vs. twice-weekly carfilzomib plus dexamethasone: subgroup analysis of the phase 3 A.R.R.O.W. study (NCT02412878) by prior lines","volume":"132","author":"Moreau","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib41","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1182\/blood-2018-99-118448","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): efficacy and safety analyzed by age group","volume":"132","author":"Dimopoulos","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2018-99-117026","article-title":"Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"132","author":"Costa","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/blood-2018-155","article-title":"Results from a phase II study of isatuximab as a single agent and in combination with dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"132","author":"Dimopoulos","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/blood-2018-153","article-title":"MOR202 with low-dose dexamethasone (Dex) or pomalidomide\/dex or lenalidomide\/dex in relapsed or refractory multiple myeloma (RRMM): primary analysis of a phase I\/IIa, multicenter, dose-escalation study","volume":"132","author":"Raab","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib45","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood-2018-99-114960","article-title":"Atezolizumab in combination with daratumumab with or without lenalidomide or pomalidomide: a phase Ib study in patients with multiple myeloma","volume":"132","author":"Cho","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib46","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood-2018-99-112610","article-title":"A\u00a0phase 1b study of oprozomib with dexamethasone or pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"132","author":"Hari","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib47","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/blood-2018-99-117201","article-title":"Deep and durable responses with selinexor, daratumumab, and dexamethasome (SDd) in patients with multiple myeloma (MM) previously exposed to proteasome inhibitors and immunomodulatory drugs: results of phase 1b study of SDd","volume":"132","author":"Gasparetto","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib48","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1182\/blood-2018-99-116663","article-title":"Results of the pivotal STORM study (part 2) in penta-refractory multiple myeloma (MM): deep and durable responses with oral selinexor plus low dose dexamethasone in patients with penta-refractory MM","volume":"132","author":"Chari","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib49","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood-2018-99-113095","article-title":"OP-106 Horizon\u2014melflufen therapy for RRMM patients refractory to daratumumab and\/or pomalidomide; updated results and first report on PFS","volume":"132","author":"Richardson","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib50","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2018-99-110548","article-title":"Updated analysis of a phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B-cell maturation antigen, in patients with relapsed\/refractory multiple myeloma","volume":"132","author":"Zhao","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib51","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-99-116898","article-title":"T\u00a0cells expressing anti B-cell maturation antigen chimeric antigen receptors for plasma cell malignancies","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib52","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2018-99-113548","article-title":"JCARH125, anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: initial proof of concept results from a phase 1\/2 multicenter study (EVOLVE)","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib53","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1182\/blood-2018-99-112786","article-title":"Durable remission achieved from Bcma-directed CAR-T therapy against relapsed or refractory multiple myeloma","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib54","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1182\/blood-2018-99-113220","article-title":"Low dose of human scFv-derived BCMA-targeted CAR-T cells achieved fast response and high complete remission in patients with relapsed\/refractory multiple myeloma","volume":"132","author":"Jiang","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib55","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2018-99-111419","article-title":"Efficacy and safety of P-Bcma-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM)","volume":"132","author":"Gregory","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib56","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2018-99-119717","article-title":"Clinical responses and pharmacokinetics of MCARH171, a human-derived Bcma targeted CAR T cell therapy in relapsed\/refractory multiple myeloma: final results of a phase I clinical trial","volume":"132","author":"Mailankody","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib57","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","article-title":"Fully human Bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma","volume":"132","author":"Green","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib58","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood-2018-99-109769","volume":"132","author":"Topp","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib59","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2018-99-113118","article-title":"Safety and efficacy of multiantigen-targeted T cells for multiple myeloma","volume":"132","author":"Lulla","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib60","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood-2018-99-111203","article-title":"Salvage autologous transplant and lenalidomide maintenance versus continuous lenalidomide\/dexamethasone for relapsed multiple myeloma: results of the randomized GMMG phase III multicenter trial relapse","volume":"132","author":"Goldschmidt","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib61","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood-2018-99-119762","article-title":"Subgroup analyses of the randomized GMMG phase III multicenter trial relapse suggest survival benefit of salvage autologous transplant primarily in low risk multiple myeloma","volume":"132","author":"Baertsch","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib62","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1182\/blood-2018-99-112116","article-title":"Ixazomib, thalidomide and dexamethasone is an effective and well tolerated re-induction regimen leading to salvage autologous stem cell transplantation (sASCT): results from the re-induction interim analysis of UK-MRA Myeloma XII (ACCoRD) trial","volume":"132","author":"Cook","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.008_bib63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2019.03.008_bib64","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2018-99-113587","article-title":"Progression-free survival subset analysis - denosumab vs. zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomized controlled phase 3 study","volume":"132","author":"Terpos","year":"2018","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019301387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019301387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:09Z","timestamp":1761870729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019301387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S2152265019301387"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting\u00a02018","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}